JPH04502013A - Hiv―1ワクチンのための合成ペプチド - Google Patents
Hiv―1ワクチンのための合成ペプチドInfo
- Publication number
- JPH04502013A JPH04502013A JP2507140A JP50714090A JPH04502013A JP H04502013 A JPH04502013 A JP H04502013A JP 2507140 A JP2507140 A JP 2507140A JP 50714090 A JP50714090 A JP 50714090A JP H04502013 A JPH04502013 A JP H04502013A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- cell epitope
- cell
- hiv
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 76
- 102000004196 processed proteins & peptides Human genes 0.000 title description 15
- 229940033332 HIV-1 vaccine Drugs 0.000 title 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 28
- 108090000623 proteins and genes Proteins 0.000 claims description 27
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 26
- 102000004169 proteins and genes Human genes 0.000 claims description 24
- 230000002163 immunogen Effects 0.000 claims description 16
- 229960005486 vaccine Drugs 0.000 claims description 13
- 210000004027 cell Anatomy 0.000 claims description 12
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 10
- 101710177291 Gag polyprotein Proteins 0.000 claims description 8
- 108091006116 chimeric peptides Proteins 0.000 claims description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 7
- 101710125418 Major capsid protein Proteins 0.000 claims description 6
- 101710132601 Capsid protein Proteins 0.000 claims description 4
- 101710091045 Envelope protein Proteins 0.000 claims description 3
- 101710188315 Protein X Proteins 0.000 claims description 3
- 102100021696 Syncytin-1 Human genes 0.000 claims description 3
- 125000000539 amino acid group Chemical group 0.000 claims description 3
- 230000001413 cellular effect Effects 0.000 claims description 2
- 210000003771 C cell Anatomy 0.000 claims 2
- 108700010908 HIV-1 proteins Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 230000005875 antibody response Effects 0.000 description 9
- 102000015636 Oligopeptides Human genes 0.000 description 8
- 108010038807 Oligopeptides Proteins 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 208000030507 AIDS Diseases 0.000 description 7
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 5
- 241000725303 Human immunodeficiency virus Species 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000011534 wash buffer Substances 0.000 description 5
- 238000011740 C57BL/6 mouse Methods 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 108010090804 Streptavidin Proteins 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 208000031886 HIV Infections Diseases 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 102000054766 genetic haplotypes Human genes 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000011803 SJL/J (JAX™ mice strain) Methods 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000036436 anti-hiv Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000006287 biotinylation Effects 0.000 description 2
- 238000007413 biotinylation Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013861 fat-free Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000009696 proliferative response Effects 0.000 description 2
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940126577 synthetic vaccine Drugs 0.000 description 2
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
- LXUNZSDDXMPKLP-UHFFFAOYSA-N 2-Methylbenzenethiol Chemical compound CC1=CC=CC=C1S LXUNZSDDXMPKLP-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 208000029483 Acquired immunodeficiency Diseases 0.000 description 1
- 101100473864 Brucella melitensis biotype 1 (strain 16M / ATCC 23456 / NCTC 10094) frr gene Proteins 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 240000006497 Dianthus caryophyllus Species 0.000 description 1
- 235000009355 Dianthus caryophyllus Nutrition 0.000 description 1
- 240000004272 Eragrostis cilianensis Species 0.000 description 1
- WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical compound F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 description 1
- 101150048348 GP41 gene Proteins 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 241000748653 Invertebrate iridescent virus 1 Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002022 anti-cellular effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108700004026 gag Genes Proteins 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (20)
- 1.HIV−1のgagタンパク質の対T−細胞エピトープのアミノ酸配列を含 む合成ペプチド。
- 2.T−細胞エピトープがタンパク質p24E(残基292〜306)を含む請 求項1に記載のペプチド。
- 3.アミノ酸配列GPKEPFRDYVDRFYK(p24E)を有する合成ペ プチド。
- 4.アミノ酸配列GPXEPFRDYVDRFYKTLRAEOASQEV(H IV1−p24)を有する合成ペプチド。
- 5.HIV−1のエンベロープまたはコアタンパク質対B−細胞エピトープのア ミノ酸配列に連結したHIV−1のgagタンパク質の対T−細胞エピトープの アミノ酸配列を含む合成キメラペプチド。
- 6.対T−細胞エピトープがp24E(残基292〜306)またはHIVl− p24である請求項5に記載のペプチド。
- 7.対B−細胞エピトープが、p24Eタンパク質のC−末端に連結したgag タンパク質の対B−細胞エピトープのC−末端に連結したコアタンパク質の対B −細胞エビトープである請求項6に記載のペプチド。
- 8.対B−細胞エピトープが、リンカー配列によってタンパク質p24EのC− 末端に接合したHIV−1エンベロープタンパク質のアミノ酸残基727〜75 1を含むBE3配列である請求項6に記載のペプチド。
- 9.対B−細胞エピトープが、リンカー配列によってタンパク質p24EのC− またはN−末端に連結した対B−細胞エピトープである請求項6に記載のペプチ ド。
- 10.リンカー配列がPPである請求項9に記載のペプチド。
- 11.対B−細胞エピトープがタンパク質P24EのN−末端に連結したBE3 を含む請求項10に記載のペプチド。
- 12.対B−細胞エピトープがHIV−1エンベロープコアタンパク質の酸残基 256〜273を含むENV配列を含む請求項10に記載のペプチド。
- 13.対B−細胞エビトープが、タンパク質P24EのN−末端に連結したHI V−1gp120タンパク質の可変ループのアミノ酸残基308〜327を含む V3A配列を含む請求項10に記載のペプチド。
- 14.有効成分として、HIV−1のgagタンパク質の対T−細胞エピトープ のアミノ酸配列を有する合成免疫原性タンパク質を含むHIV−1に対するワク チン。
- 15.対T−細胞エピトープがタンパク質p24Eまたはタンパク質HIV−1 −p24である請求項14に記載のワクチン。
- 16.対T−細胞エピトープがHIV−1タンパク質の対B−細胞エピトープに 対応する合成タンパク質に連結している請求項15に記載のワクチン。
- 17.対B−細胞エピトープがBE3、ENVまたはV3Aタンパク質である請 求項16に記載のワクチン。
- 18.対B−細胞エピトープがgagタンパク質のC−末端に接合している請求 項17に記載のワクチン。
- 19.対B−細胞エピトープがリンカー配列によってC−末端に接合している請 求項17または18に記載のワクチン。
- 20.B−細胞エピトープが、PPからなるリンカー配列によってgagタンパ ク質に接合したBE3、ENVまたはV3Aタンパク質である請求項16に記載 のワクチン。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB898910145A GB8910145D0 (en) | 1989-05-03 | 1989-05-03 | Synthetic peptides for an hiv-1 vaccine |
GB8910145.5 | 1989-05-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH04502013A true JPH04502013A (ja) | 1992-04-09 |
JP2609764B2 JP2609764B2 (ja) | 1997-05-14 |
Family
ID=10656139
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2507140A Expired - Lifetime JP2609764B2 (ja) | 1989-05-03 | 1990-05-03 | Hiv―1ワクチンのための合成ペプチド |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0470980B1 (ja) |
JP (1) | JP2609764B2 (ja) |
AT (1) | ATE102217T1 (ja) |
CA (1) | CA2053921C (ja) |
DE (1) | DE69007099T2 (ja) |
DK (1) | DK0470980T3 (ja) |
ES (1) | ES2062521T3 (ja) |
GB (1) | GB8910145D0 (ja) |
WO (1) | WO1990013564A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008271974A (ja) * | 1994-10-20 | 2008-11-13 | Inst Pasteur | Hiv−1のoグループ(またはサブグループ)レトロウイルス性抗原のヌクレオチド配列 |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4039925A1 (de) * | 1990-12-14 | 1992-06-17 | Behringwerke Ag | Ausgewaehlte peptide des gruppenspezifischen antigens (gag) von humanem immundefizienzvirus (hiv), ihre herstellung und verwendung |
JPH0748276A (ja) * | 1992-03-26 | 1995-02-21 | Inmeru:Kk | Hiv感染症予防ワクチンおよびその製造法 |
GB9208218D0 (en) * | 1992-04-14 | 1992-05-27 | British Bio Technology | Hybrid particles |
CN1111540C (zh) * | 1993-06-09 | 2003-06-18 | 康诺特实验室有限公司 | 串联的合成hiv-1肽类 |
US5693325A (en) * | 1994-03-15 | 1997-12-02 | Molecumetics, Ltd. | Peptide vaccines and methods relating thereto |
FR2731225B1 (fr) * | 1995-03-03 | 2003-10-31 | Pasteur Institut | Peptides de glycoproteine transmembranaire d'enveloppe et de proteine de capside du retrovirus humain du type hiv-1 et peptides presentant avec eux une parente immunologique |
FR2734281B1 (fr) * | 1995-05-18 | 1997-07-25 | Commissariat Energie Atomique | Fragments d'acide nucleique derives du genome du virus vih-1, peptides correspondants et leurs applications en tant que reactifs d'evaluation du risque de transmission materno-foetale du vih-1 |
US5972339A (en) * | 1997-11-13 | 1999-10-26 | The General Hospital Corporation | Method of eliciting anti-HIV-1 helper T cell responses |
US7105164B1 (en) | 1998-04-07 | 2006-09-12 | Sanofi Pasteur Limited | HIV-specific cytotoxic T-cell responses |
US6395714B1 (en) | 1999-02-24 | 2002-05-28 | Aventis Pasteur Limited | Expressing gp140 fragment of primary HIV-1 isolate |
US20090028874A1 (en) * | 2003-12-24 | 2009-01-29 | Leiden University Medical Center | Synthetic Protein as Tumor-Specific Vaccine |
FR2882557A1 (fr) * | 2005-02-25 | 2006-09-01 | Centre Nat Rech Scient | Epitopes de vih et composition pharmaceutique les contenant |
GB0716494D0 (en) * | 2007-08-23 | 2007-10-03 | Isis Innovation | HIV-2 antigenic peptides |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ230372A (en) * | 1984-10-18 | 1994-02-25 | Pasteur Institut | Hiv antigen, assay and vaccine. |
DE3650175T3 (de) * | 1985-04-29 | 2007-09-06 | Bio-Rad Laboratories, Inc., Hercules | Synthetische antigene zum nachweis von aids. |
WO1987002775A1 (en) * | 1985-10-24 | 1987-05-07 | Southwest Foundation For Biomedical Research | Synthetic peptides and use for diagnosis and vaccination for aids and arc |
EP0273716B1 (en) * | 1986-12-30 | 1993-08-11 | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce | Synthetic peptides which induce cellular immunity to the aids virus and aids viral proteins |
DE3850593T3 (de) * | 1987-03-25 | 2001-01-04 | Pasteur Institut | Synthetische Antigene zur Bestimmung der AIDS-bezogenen, von LAV-2 verursachten Krankheiten. |
CA1339363C (en) * | 1987-05-01 | 1997-08-26 | Alan Ray Flesher | Monoclonal antibodies to specific antigenic regions of the human immunodeficiency virus and methods for use |
-
1989
- 1989-05-03 GB GB898910145A patent/GB8910145D0/en active Pending
-
1990
- 1990-05-03 DE DE69007099T patent/DE69007099T2/de not_active Expired - Lifetime
- 1990-05-03 WO PCT/CA1990/000146 patent/WO1990013564A1/en active IP Right Grant
- 1990-05-03 EP EP90906803A patent/EP0470980B1/en not_active Expired - Lifetime
- 1990-05-03 ES ES90906803T patent/ES2062521T3/es not_active Expired - Lifetime
- 1990-05-03 JP JP2507140A patent/JP2609764B2/ja not_active Expired - Lifetime
- 1990-05-03 DK DK90906803.3T patent/DK0470980T3/da active
- 1990-05-03 CA CA002053921A patent/CA2053921C/en not_active Expired - Lifetime
- 1990-05-03 AT AT90906803T patent/ATE102217T1/de not_active IP Right Cessation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008271974A (ja) * | 1994-10-20 | 2008-11-13 | Inst Pasteur | Hiv−1のoグループ(またはサブグループ)レトロウイルス性抗原のヌクレオチド配列 |
JP4589420B2 (ja) * | 1994-10-20 | 2010-12-01 | アンスティテュ・パストゥール | Hiv−1のoグループ(またはサブグループ)レトロウイルス性抗原のヌクレオチド配列 |
Also Published As
Publication number | Publication date |
---|---|
DK0470980T3 (da) | 1994-03-28 |
CA2053921A1 (en) | 1990-11-04 |
EP0470980A1 (en) | 1992-02-19 |
CA2053921C (en) | 1999-07-20 |
DE69007099D1 (de) | 1994-04-07 |
WO1990013564A1 (en) | 1990-11-15 |
DE69007099T2 (de) | 1994-06-01 |
ES2062521T3 (es) | 1994-12-16 |
JP2609764B2 (ja) | 1997-05-14 |
EP0470980B1 (en) | 1994-03-02 |
GB8910145D0 (en) | 1989-06-21 |
ATE102217T1 (de) | 1994-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5817318A (en) | Synthetic peptides for an HIV-1 vaccine | |
AU693098B2 (en) | Tandem synthetic HIV-1 peptides | |
US8110203B2 (en) | Adjuvant comprising non-toxic cross-linked muramyl dipeptide (MDP) microparticles derived from Propionibacterium acnes | |
US5019387A (en) | Production of antibodies to HIV | |
US5013548A (en) | Production of antibodies to HIV | |
US5166050A (en) | Monoclonal antibodies and peptides useful in treating and diagnosing HIV infections | |
WO1990003984A1 (en) | Hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids | |
US20030003440A1 (en) | Novel CCR5 epitope and antibodies against it | |
AU6523590A (en) | Novel peptides associated with the cd4 binding region of gp120 and their methods of use | |
US6447778B1 (en) | Peptide compositions for the treatment of HIV infection | |
JPH04502013A (ja) | Hiv―1ワクチンのための合成ペプチド | |
GB2196634A (en) | Monoclonal antibodies to HIV and related peptides | |
US6210873B1 (en) | Methods and compositions for the priming of specific cytotoxic T-lymphocyte response | |
Iglesias et al. | Broader cross-reactivity after conjugation of V3 based multiple antigen peptides to HBsAg | |
Chong et al. | Identification of a potent synthetic HIV1 immunogen compromising gag‐P24 tandem T‐and B‐cell epitopes | |
AU2006200454B2 (en) | Compositions and methods for treating viral infections | |
Torres et al. | SIV envelope glycoprotein epitopes recognized by antibodies from infected or vaccinated rhesus macaques | |
JP2007534615A (ja) | Hiv免疫原性複合体 | |
KR100348183B1 (ko) | 텐덤합성hiv-1펩티드들 | |
Ding et al. | Induction of multi-epitopespecific antibodies against HIV-1 by multi-epitopevaccines | |
AU2004201321A1 (en) | Compositions and methods for treating viral infections | |
AU2004208648A1 (en) | Compositions and methods for treating infections | |
AU2006200455A1 (en) | Compositions and methods for treating viral infections |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080213 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090213 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100213 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100213 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110213 Year of fee payment: 14 |
|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110213 Year of fee payment: 14 |